De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!
AB Science Toekomstige groei
Future criteriumcontroles 1/6
AB Science's earnings are forecast to decline at 8.6% per annum while its annual revenue is expected to grow at 7.2% per year. EPS is expected to decline by 13.4% per annum.
Belangrijke informatie
-8.6%
Groei van de winst
-13.4%
Groei van de winst per aandeel
Pharmaceuticals winstgroei | 17.7% |
Inkomstengroei | 7.2% |
Toekomstig rendement op eigen vermogen | n/a |
Dekking van analisten | Low |
Laatst bijgewerkt | 14 Mar 2024 |
Winst- en omzetgroeiprognoses
Datum | Inkomsten | Inkomsten | Vrije kasstroom | Geldmiddelen uit operationele activiteiten | Gem. Aantal analisten |
---|---|---|---|---|---|
12/31/2026 | 1 | -17 | -20 | -19 | 1 |
12/31/2025 | 1 | -18 | -19 | -18 | 1 |
12/31/2024 | 1 | -19 | -18 | -18 | 1 |
12/31/2023 | 1 | -12 | -17 | -17 | N/A |
9/30/2023 | 1 | -14 | N/A | N/A | N/A |
6/30/2023 | 1 | -17 | -19 | -18 | N/A |
3/31/2023 | 1 | -15 | -18 | -18 | N/A |
12/31/2022 | 1 | -14 | -18 | -17 | N/A |
9/30/2022 | 1 | -15 | N/A | N/A | N/A |
6/30/2022 | 1 | -17 | -18 | -17 | N/A |
3/31/2022 | 2 | -16 | -18 | -17 | N/A |
12/31/2021 | 2 | -14 | -18 | -17 | N/A |
9/30/2021 | 2 | -13 | -16 | -16 | N/A |
6/30/2021 | 2 | -11 | -15 | -14 | N/A |
3/31/2021 | 2 | -13 | -14 | -14 | N/A |
12/31/2020 | 2 | -15 | -14 | -14 | N/A |
9/30/2020 | 2 | -16 | -13 | -13 | N/A |
6/30/2020 | 2 | -18 | -12 | -12 | N/A |
3/31/2020 | 2 | -20 | -14 | -14 | N/A |
12/31/2019 | 2 | -22 | -16 | -15 | N/A |
9/30/2019 | 2 | -25 | -18 | -18 | N/A |
6/30/2019 | 2 | -28 | -21 | -20 | N/A |
3/31/2019 | 2 | -27 | -24 | -23 | N/A |
12/31/2018 | 2 | -26 | -27 | -27 | N/A |
9/30/2018 | 2 | -25 | -28 | -27 | N/A |
6/30/2018 | 2 | -25 | -28 | -28 | N/A |
3/31/2018 | 2 | -26 | -26 | -25 | N/A |
12/31/2017 | 2 | -27 | -23 | -23 | N/A |
9/30/2017 | 2 | -27 | N/A | -26 | N/A |
6/30/2017 | 2 | -26 | N/A | -28 | N/A |
3/31/2017 | 2 | -27 | N/A | -31 | N/A |
12/31/2016 | 2 | -28 | N/A | -34 | N/A |
9/30/2016 | 2 | -28 | N/A | -31 | N/A |
6/30/2016 | 2 | -28 | N/A | -28 | N/A |
3/31/2016 | 2 | -28 | N/A | -26 | N/A |
12/31/2015 | 2 | -27 | N/A | -23 | N/A |
9/30/2015 | 2 | -24 | N/A | -22 | N/A |
6/30/2015 | 2 | -22 | N/A | -21 | N/A |
3/31/2015 | 2 | -19 | N/A | -17 | N/A |
12/31/2014 | 2 | -16 | N/A | -14 | N/A |
9/30/2014 | 2 | -16 | N/A | -13 | N/A |
6/30/2014 | 2 | -15 | N/A | -12 | N/A |
3/31/2014 | 2 | -15 | N/A | -12 | N/A |
12/31/2013 | 2 | -15 | N/A | -13 | N/A |
Toekomstige groeivoorspellingen analisten
Verdiensten versus spaarpercentage: AB is forecast to remain unprofitable over the next 3 years.
Winst versus markt: AB is forecast to remain unprofitable over the next 3 years.
Hoge groeiwinsten: AB is forecast to remain unprofitable over the next 3 years.
Omzet versus markt: AB's revenue (7.2% per year) is forecast to grow faster than the French market (5.7% per year).
Hoge groei-inkomsten: AB's revenue (7.2% per year) is forecast to grow slower than 20% per year.
Groeiprognoses winst per aandeel
Toekomstig rendement op eigen vermogen
Toekomstige ROE: Insufficient data to determine if AB's Return on Equity is forecast to be high in 3 years time